The concept of brain-computer interfaces in the US stock market is being hyped, and Regencell Bioscience continues to rise over 20% in after-hours trading

Regencell Bioscience's stock price surged 283% on June 13th Eastern Time, reaching a historic high with a market value exceeding $29.6 billion, and continued to rise over 20% in after-hours trading. The company's next-generation neural modulation chip has received FDA clinical trial approval and will collaborate with the Mayo Clinic to research Parkinson's disease. Recently, there has been a flurry of news in the brain-computer interface field, increasing market interest. McKinsey estimates that the global medical application market could reach $40 billion to $145 billion between 2030 and 2040.

Regencell Bioscience is an early-stage bioscience company that started in Hong Kong in 2014, with its main operations and assets located in Hong Kong. Currently, it has 12 employees and focuses on researching, developing, and commercializing traditional Chinese medicine for treating neurocognitive disorders and degeneration, particularly Attention Deficit Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD). It plans to launch three standardized liquid traditional Chinese medicine formulas suitable for mild, moderate, and severe ADHD and ASD patients in Hong Kong first, and then expand to other markets as deemed appropriate.

The company's stock price was ignited by the highly anticipated brain-computer interface technology. On May 9th, Regencell Bioscience announced that its next-generation neural modulation chip had passed FDA clinical trial approval and would collaborate with the world-renowned Mayo Clinic to conduct research on Parkinson's disease treatment. This neural modulation chip technology is at the forefront of the brain-computer interface field, and the company plans to utilize this technology to conduct research on Parkinson's disease, targeting a global market of approximately 10 million patients.

Since the beginning of this year, there has been a continuous stream of significant news in the brain-computer interface field, with policies heating up, and breakthroughs in corporate financing and clinical progress. For instance, "tech mogul" Elon Musk's brain-computer interface company Neuralink announced the completion of a new round of financing of $650 million (approximately 4.3 billion RMB), with a pre-investment valuation soaring to $9 billion (approximately 65 billion RMB). Additionally, China successfully conducted its first invasive brain-computer interface clinical trial, and the first brain-computer interface medical service pricing was implemented in Hubei... These developments have reignited global interest in the brain-computer interface industry.

McKinsey estimates that the potential market size for the application of brain-computer interfaces in the medical field could reach $40 billion to $145 billion between 2030 and 2040